CTOs on the Move

DR Management

www.dr-management.com

 
DR Management is a Fort Wayne, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Fibrocell Science

Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.

Gurwin Jewish Nursing and Rehabilitation Center

Gurwin Jewish Nursing and Rehabilitation Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Gurwin Jewish Nursing and Rehabilitation Center is based in Commack, NY. You can find more information on Gurwin Jewish Nursing and Rehabilitation Center at www.gurwin.org

Questcare Management Svc Inc

Questcare Management Svc Inc is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Applied Biometrics

Applied Biometrics is a Glendale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.